Malignant Pleural Mesothelioma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology

The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Malignant Pleural Mesothelioma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Malignant Pleural Mesothelioma Market.

Some of the key takeaways from the Malignant Pleural Mesothelioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Malignant Pleural Mesothelioma treatment therapies with a considerable amount of success over the years. 
• Malignant Pleural Mesothelioma companies working in the treatment market are Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others, are developing therapies for the Malignant Pleural Mesothelioma treatment 

• Emerging Malignant Pleural Mesothelioma therapies in the different phases of clinical trials are- INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others are expected to have a significant impact on the Malignant Pleural Mesothelioma market in the coming years.   
• In December 2022, Amphera published efficacy and safety results from the phase II/III DENIM study in mesothelioma.
• In September 2022, The US FDA granted Pegargiminase Fast track status for mesothelioma treatment.
• In June 2022, In the United States (Intratumoural), Momotaro-Gene stated that enrollment in their phase II trial for mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or larger) had reached its completion.
• In March 2021, Patients with second- and third-line malignant pleural mesothelioma (PEMMELA) were given Pembrolizumab plus Lenvatinib. The trial is still ongoing and not recruiting participants.
• In 2015 , MTG-201 was given Orphan Drug Designation by the US FDA to treat malignant mesothelioma.

Malignant Pleural Mesothelioma Overview

cancerous pleura Mesothelial cells of the pleura give rise to the aggressive malignancy known as mesothelioma (MPM). The “visceral” and “parietal” pleuras, as well as the diaphragm, the heart, and the main blood veins in the central region of the chest, are both covered by the pleura, a thin cellular lining.

Get a Free Sample PDF Report to know more about Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight

Emerging Malignant Pleural Mesothelioma Drugs Under Different Phases of Clinical Development Include:

• INBRX-109: Inhibrx
• NX-1607: Nurix Therapeutics
• ATA2271: Atara Biotherapeutics
• TC-510: TCR2 Therapeutics
• RSO-021: RS Oncology
• SAR-444245: Sanofi
• MTG201: MomotaroGene
• Durvalumab: AstraZeneca
• Pembrolizumab: Merck & Co
• MesoPher: Amphera BV
• Pegargiminase: Polaris Pharmaceuticals
• Galinpepimut-S (Vaccine): Sellas Life Sciences Group
• ZEPZELCA (lurbinectedin): PharmaMar
• IMFINZI: AstraZeneca
• ONCOS-102: Targovax
• TC-210: TCR2 Therapeutics
• TECENTRIQ Plus AVASTIN: Hoffmann-La Roche

Malignant Pleural Mesothelioma Route of Administration

Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Malignant Pleural Mesothelioma Molecule Type

Malignant Pleural Mesothelioma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type 

Malignant Pleural Mesothelioma Pipeline Therapeutics Assessment

• Malignant Pleural Mesothelioma Assessment by Product Type
• Malignant Pleural Mesothelioma By Stage and Product Type
• Malignant Pleural Mesothelioma Assessment by Route of Administration
• Malignant Pleural Mesothelioma By Stage and Route of Administration
• Malignant Pleural Mesothelioma Assessment by Molecule Type
• Malignant Pleural Mesothelioma by Stage and Molecule Type

DelveInsight’s Malignant Pleural Mesothelioma Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Malignant Pleural Mesothelioma product details are provided in the report. Download the Malignant Pleural Mesothelioma pipeline report to learn more about the emerging Malignant Pleural Mesothelioma therapies

Some of the key companies in the Malignant Pleural Mesothelioma Therapeutics Market include:

Key companies developing therapies for Malignant Pleural Mesothelioma are – Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, Novartis,  MolMed, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd, AGC Biologics S.p.A, Aduro Biotech, Inc, Bristol-Myers Squibb, Novotech (Australia) Pty Limited, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others.

Malignant Pleural Mesothelioma Pipeline Analysis:

The Malignant Pleural Mesothelioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma Treatment.
• Malignant Pleural Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malignant Pleural Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Malignant Pleural Mesothelioma drugs and therapies

Malignant Pleural Mesothelioma Pipeline Market Drivers

• Increased adoption of combination therapies are some of the important factors that are fueling the Malignant Pleural Mesothelioma Market.

Malignant Pleural Mesothelioma Pipeline Market Barriers

• However, treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, high Cost of Treatment and other factors are creating obstacles in the Malignant Pleural Mesothelioma Market growth.

Scope of Malignant Pleural Mesothelioma Pipeline Drug Insight    

• Coverage: Global
• Key Malignant Pleural Mesothelioma Companies: Inhibrx, Nurix Therapeutics, Atara Biotherapeutics, TCR2 Therapeutics, RS Oncology, Sanofi, MomotaroGene, AstraZeneca, Merck & Co, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others
• Key Malignant Pleural Mesothelioma Therapies: INBRX-109, NX-1607, ATA2271, TC-510, RSO-021, SAR-444245, MTG201, Durvalumab, Pembrolizumab, MesoPher, Pegargiminase, Galinpepimut-S (Vaccine), ZEPZELCA (lurbinectedin), IMFINZI, ONCOS-102, TC-210, TECENTRIQ Plus AVASTIN, and others
• Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
• Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers 

Request for Sample PDF Report for Malignant Pleural Mesothelioma Pipeline Assessment and clinical trials

Table of Contents 

1. Malignant Pleural Mesothelioma Report Introduction

2. Malignant Pleural Mesothelioma Executive Summary

3. Malignant Pleural Mesothelioma Overview

4. Malignant Pleural Mesothelioma- Analytical Perspective In-depth Commercial Assessment

5. Malignant Pleural Mesothelioma Pipeline Therapeutics

6. Malignant Pleural Mesothelioma Late Stage Products (Phase II/III)

7. Malignant Pleural Mesothelioma Mid Stage Products (Phase II)

8. Malignant Pleural Mesothelioma Early Stage Products (Phase I)

9. Malignant Pleural Mesothelioma Preclinical Stage Products

10. Malignant Pleural Mesothelioma Therapeutics Assessment

11. Malignant Pleural Mesothelioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Malignant Pleural Mesothelioma Key Companies

14. Malignant Pleural Mesothelioma Key Products

15. Malignant Pleural Mesothelioma Unmet Needs

16 . Malignant Pleural Mesothelioma Market Drivers and Barriers

17. Malignant Pleural Mesothelioma Future Perspectives and Conclusion

18. Malignant Pleural Mesothelioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services